SOMERSET, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- CareCloud, Inc. (Nasdaq: CCLD, CCLDP, CCLDO), a leader in healthcare technology solutions for medical practices and health systems nationwide, announced today that Hadi Chaudhry and Stephen Snyder, CareCloud’s chief executive officer and president, will be discussing the use of generative AI in healthcare in a fireside chat on Tuesday, June 4, 2024.
The Company will be taking part in a virtual conference sponsored by Maxim Group entitled “Charting the Course: Navigating the Intersection of TMT and Business in the AI Era.” The continuous evolution of technology is paving the way for innovation across all industries, and CareCloud’s leadership will discuss how CareCloud is using generative AI to help its customers, 2,600 physician practices throughout the United States, reap the benefits of generative AI.
To register for the events or to learn more about upcoming events, please visit CareCloud's investor relations site, ir.carecloud.com/news-events/ir-calendar.
About CareCloud
CareCloud (Nasdaq: CCLD, CCLDP, CCLDO) brings disciplined innovation to the business of healthcare. Our suite of technology-enabled solutions helps clients increase financial and operational performance, streamline clinical workflows and improve patient experience. More than 40,000 providers count on CareCloud to help them improve patient care while reducing administrative burdens and operating costs. Learn more about our products and services, including revenue cycle management (RCM), practice management (PM), electronic health records (EHR), business intelligence, patient experience management (PXM) and digital health, at www.carecloud.com.
Follow CareCloud on LinkedIn, Twitter and Facebook.
Investor Contact:
Bill Korn
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$2.02 |
| Daily Change: | -0.04 -1.71 |
| Daily Volume: | 171,526 |
| Market Cap: | US$32.760M |
May 06, 2025 April 07, 2025 April 02, 2025 March 26, 2025 March 13, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
